Sarepta Therapeutics, Inc. (SRPT), Friday acknowledged the Committee for Medicinal Products for Human Use's negative opinion on the conditional marketing authorization for ELEVIDYS in ambulatory individuals ages three to seven years for the treatment of Duchenne muscular dystrophy.
Meanwhile, its partner Roche will continue its dialogue with the European Medicines Agency to explore a potential path forward to make ELEVIDYS available in the region.
Further, the company stated that ELEVIDYS showed clinically meaningful and statistically significant improvements across important secondary endpoints of functional outcome measures in EMBARK study. However, it did not meet the primary endpoint of the study.
In the pre-market hours, SRPT is moving down 10.64 percent, to $11.50 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.